Abstract 99P
Background
Generally, cancer cell lines are established from the patients of which cancer cells are dissected, cultured and maintained in vitro. These cell lines have been traditionally used in cancer research; however, they have changed better to survive in culture condition in vitro, and not restored the original characters when they grew in vivo, meaning the lack of tumor heterogeneity. Primary culture of cancer cells derived from patients’ tumors can provide crucial information as each “individual tumor”. The primary culture method of clinical cancer and the evaluation for the treatment have not been clearly optimized in gastrointestinal cancers.
Methods
We have developed a simple 2D/3D-culture method for primary cancer. We obtained 40 clinical samples from surgically resected colorectal cancers (CRCs). They were mechanically and enzymatically digested and are filtered by customized preparation tools, followed by in vitro culture system. The gene expression profiles and the sensitivity for the drugs were analyzed.
Results
Culture cells were analyzed These cultured cancer cells were named “isolated-tumor derived Cancer Cells (iCCs).” All iCCs grew and about 90 % of iCCs were successfully passaged. These iCCs were transplanted into the subcutaneous tissue of nonobese diabetic (NOD) - severely compromised immune deficient (SCID) mice, and the tumor growth and pathological examination were evaluated. The morphology was similar to each parental clinical tumor. Microarray analyses showed that RNA expression of iCCs was similar to each parental tumor. Surface markers regarding cancer stem cells expressed in iCCs. Furthermore, multi-drug sensitivity assay by our bespoke plates including commonly used as anti-cancer/molecular target drugs was performed.
Conclusions
The iCCs are very similar to each parental tumor, leading to the personalized medicine, and the analyses of the tumor characteristics seem to reflect the clinical presentation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japanese Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract